8-K: Verrica Pharmaceuticals Nears Nasdaq Compliance After Reverse Stock Split

Verrica Pharmaceuticals Inc. is actively working to regain compliance with Nasdaq's minimum bid price requirement following a delisting notice, implementing a reverse stock split and showing progress towards continued listing.

Summary

• Verrica Pharmaceuticals Inc. received a delisting notice from The Nasdaq Stock Market LLC on July 24, 2025, for failing to maintain a minimum closing bid price of $1.00 per share (Nasdaq Listing Rule 5450(a)(1)).
• The company did not regain compliance within the 180-calendar day grace period, which ended on July 23, 2025.
• Verrica intends to timely request a hearing before a Nasdaq Hearings Panel, which automatically stays any suspension or delisting of its securities.
• To regain compliance, the common stock's closing bid price must be at least $1.00 per share for 10 to 20 consecutive business days.
• On July 24, 2025, the company effected a 1-for-10 reverse stock split to increase its per-share closing bid price.
• As of July 29, 2025, the common stock's closing bid price was $6.24, and it has been in compliance with the Minimum Bid Price Requirement for four consecutive business days.
• The company plans to request a bid price compliance determination and the cancellation of the hearing after achieving ten trading days of bid price compliance.

Sentiment

Score: 4

Explanation: While the company is actively addressing the delisting issue and showing progress towards regaining compliance, the initial delisting notice and the necessity of a reverse stock split indicate underlying challenges with stock valuation and market perception. The situation is improving but still carries risk until full compliance is officially confirmed.

Positives

• The company intends to timely request a hearing before the Nasdaq Hearings Panel, which automatically stays any suspension or delisting.
• A 1-for-10 reverse stock split was successfully effected on July 24, 2025, to increase the per-share price.
• As of July 29, 2025, the common stock's closing bid price was $6.24, significantly exceeding the $1.00 minimum bid price requirement.
• The common stock has been in compliance with the Minimum Bid Price Requirement for four consecutive business days.
• The company plans to request a bid price compliance determination and cancellation of the hearing after ten trading days of compliance, indicating a clear path forward.

Negatives

• Received a delisting notice from Nasdaq on July 24, 2025, due to non-compliance with the Minimum Bid Price Requirement ($1.00 per share).
• Failed to regain compliance within the initial 180-calendar day grace period, which ended on July 23, 2025.

Risks

• Risks, uncertainties, and assumptions related to the trading price of the Common Stock.
• Risks disclosed under Item 1A, "Risk Factors," in the company's most recently filed Annual Report on Form 10-K, as updated by subsequently filed Quarterly Report on Form 10-Q.

Future Outlook

The company expects its common stock to continue to be listed and traded on The Nasdaq Global Market pending the conclusion of the hearings process. It intends to request a bid price compliance determination and the cancellation of the hearing once the common stock maintains a closing bid price of at least $1.00 per share for ten consecutive business days.

Management Comments

• "The Company intends to timely request a hearing before the Panel."
• "The Company expects that its common stock will continue to be listed and traded on The Nasdaq Global Market pending the conclusion of the hearings process."
• "The primary purpose for the reverse stock split was to increase the per-share closing bid price of the Companys common stock so as to demonstrate compliance with the Minimum Bid Price Requirement and to help ensure the Companys continued listing on Nasdaq."
• "Following ten trading days of bid price compliance, the Company intends to request a bid price compliance determination and the cancellation of the hearing."

Industry Context

This announcement is specific to Verrica Pharmaceuticals' compliance with Nasdaq listing rules. While minimum bid price challenges can affect companies across various sectors, particularly smaller capitalization firms, this filing does not provide information to indicate a broader industry trend or specific competitive implications.

Stakeholder Impact

• Shareholders: Potential for continued listing on Nasdaq, which preserves liquidity and visibility. The reverse stock split reduces the number of shares outstanding and increases the per-share price, which can be perceived positively or negatively depending on individual investor perspective. The risk of delisting remains until full compliance is achieved and confirmed.

Next Steps

• Timely request a hearing before the Nasdaq Hearings Panel.
• Achieve a closing bid price of at least $1.00 per share for at least 10 consecutive business days (up to 20 business days, at Nasdaq's discretion).
• Request a bid price compliance determination and cancellation of the hearing after achieving ten trading days of bid price compliance.

Key Dates

Recommendation

The company is actively addressing a significant listing issue with a clear plan (reverse stock split, hearing request, working towards 10-day compliance). While the initial delisting notice is a negative, the proactive steps and current compliance status (4 days in compliance, $6.24 bid price) suggest a path to resolution. However, full compliance is not yet achieved, and the underlying reasons for the low bid price (prior to the split) are not addressed in this filing. A 'Hold' recommendation reflects the ongoing efforts to stabilize the listing status, but acknowledges the remaining uncertainty until the 10-day compliance period is met and the hearing is cancelled.

Keywords

Verrica Pharmaceuticals, VRCA, Nasdaq, delisting, reverse stock split, minimum bid price, listing compliance, stock market, pharmaceutical